2018
Is it safe to stop oral anticoagulation after catheter ablation for atrial fibrillation?
Romero J, Avendano R, Diaz J, Taveras J, Lupercio F, Di Biase L. Is it safe to stop oral anticoagulation after catheter ablation for atrial fibrillation? Expert Review Of Cardiovascular Therapy 2018, 17: 31-41. PMID: 30460874, DOI: 10.1080/14779072.2019.1550718.Peer-Reviewed Original ResearchConceptsCatheter ablationAtrial fibrillationOral anticoagulantsOral anticoagulationBlanking periodRisk of bleedingSociety guidelinesCommon arrhythmiaCurrent guidelinesFibrillationAnticoagulantsRelevant articlesMajor databasesAnticoagulationAblationRiskGuidelinesBleedingEMBASEArrhythmiasPubMedStrokeMajor recommendationsPrevalenceBivalirudin versus heparin in patients undergoing percutaneous peripheral interventions: A systematic review and meta-analysis
Olmedo W, Villablanca P, Sanina C, Walker J, Weinreich M, Brevik J, Avendano R, Bravo C, Romero J, Ramakrishna H, Babaev A, Attubato M, Hernandez-Suarez D, Cox-Alomar P, Pyo R, Krishnan P, Wiley J. Bivalirudin versus heparin in patients undergoing percutaneous peripheral interventions: A systematic review and meta-analysis. Vascular 2018, 27: 78-89. PMID: 30501582, DOI: 10.1177/1708538118807522.Peer-Reviewed Original ResearchConceptsPercutaneous peripheral interventionsAccess site complicationsPeripheral interventionsCause mortalitySite complicationsMinor bleedingSystematic reviewEfficacy of bivalirudinProcedural anticoagulant agentLarge randomized trialsSignificant differencesBivalirudin useMajor bleedingIntracranial bleedingBlood transfusionRandomized trialsMyocardial infarctionAnticoagulant agentsClinical studiesBivalirudinBleedingComplicationsPatientsHeparinMortalityClinical outcomes in patients with atrial fibrillation receiving amiodarone on NOACs vs. warfarin
Avendano R, Romero J, Lupercio F, Diaz J, Quispe R, Golive A, Natale A, Garcia M, Krumerman A, Di Biase L. Clinical outcomes in patients with atrial fibrillation receiving amiodarone on NOACs vs. warfarin. Journal Of Interventional Cardiac Electrophysiology 2018, 54: 73-80. PMID: 30128801, DOI: 10.1007/s10840-018-0427-y.Peer-Reviewed Original ResearchConceptsNew oral anticoagulantsMajor bleedingAtrial fibrillationThromboembolic eventsIntracranial bleedingClinical outcomesRisk ratioStroke/thromboembolic eventsRecent retrospective trialsMantel-Haenszel methodConclusionAmong patientsTE preventionOral anticoagulantsIncreased riskRetrospective trialsResultsA totalHigh riskAmiodaroneBleedingPatientsWarfarinSystematic reviewP-glycoproteinConfidence intervalsOutcomesBenefit of left atrial appendage electrical isolation for persistent and long-standing persistent atrial fibrillation: a systematic review and meta-analysis
Romero J, Michaud G, Avendano R, Briceño D, Kumar S, Diaz J, Mohanty S, Trivedi C, Gianni C, Della Rocca D, Proietti R, Perrotta L, Bordignon S, Chun J, Schmidt B, Garcia M, Natale A, Di Biase L. Benefit of left atrial appendage electrical isolation for persistent and long-standing persistent atrial fibrillation: a systematic review and meta-analysis. EP Europace 2018, 20: 1268-1278. PMID: 29342299, DOI: 10.1093/europace/eux372.Peer-Reviewed Original ResearchConceptsAtrial appendage electrical isolationPersistent atrial fibrillationAtrial fibrillationIschemic strokeSystematic reviewNon-paroxysmal AF patientsStandard ablationNon-paroxysmal atrial fibrillationAcute procedural complicationsIncremental benefitAcute complication rateLong-term outcomesAntiarrhythmic medicationsArrhythmia recurrenceComplication rateAF patientsProcedural complicationsCatheter ablationAtrial arrhythmiasClinical studiesOverall freedomLAAEIPatientsLSPAFFibrillation
2017
Clinical impact of implantable cardioverter-defibrillator in primary prevention of total mortality in non-ischaemic cardiomyopathy: results from a meta-analysis of prospective randomized clinical trials
Romero J, Díaz J, Grushko M, Quispe R, Briceno D, Avendano R, Golive A, Pina I, Natale A, Garcia M, Jorde U, Di Biase L. Clinical impact of implantable cardioverter-defibrillator in primary prevention of total mortality in non-ischaemic cardiomyopathy: results from a meta-analysis of prospective randomized clinical trials. EP Europace 2017, 20: f211-f216. PMID: 29161424, DOI: 10.1093/europace/eux324.Peer-Reviewed Original ResearchConceptsNon-ischemic cardiomyopathyImplantable cardioverter defibrillatorCause mortalityNICM patientsPrimary ProphylacTic Implantable Cardioverter DefibrillatorsRole of ICDUse of ICDsTotal mortalityProphylactic implantable cardioverter defibrillatorProspective randomized clinical trialsCardiac resynchronization therapy pacemakerCause mortality benefitProphylactic ICD placementMedical therapy groupRandomized clinical trialsRandom-effects modelSignificant reductionFixed-effects modelMean followMortality benefitICD groupIschemic cardiomyopathyMedical therapyICD placementTreatment arms